Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS MANUFACTURING TEAM: ADDS DIRECTOR OF TECHNICAL OPERATIONS AND MANAGER OF PRODUCTION

 TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS MANUFACTURING TEAM:
 ADDS DIRECTOR OF TECHNICAL OPERATIONS AND MANAGER OF PRODUCTION
 WOBURN, Mass., Aug. 25 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. today announced that it has appointed Thomas Rossolillo to director of technical operations and Stephen R. Potter, formerly of Biogen, Inc., to manager of production.
 "Rossolillo's extensive background in facilities and process planning and Potter's experience in pharmaceutical manufacturing add significant expertise to Telor's manufacturing operations," said Stephen J. Riggi, Ph.D, president and chief executive officer of Telor. "Plans are underway to expand our manufacturing capability, which will support the expansion of the clinical trials for our intraocular pressure- lowering drug EY-105 and other products in development."
 Telor's EY-105 is currently in Phase II clinical trials to control transient, acute rises in intraocular pressure that can occur following ophthalmic surgery. Preclinical studies with a topical product are in progress to investigate the use of EY-105 for the treatment of glaucoma, a disease characterized by a chronic increase in intraocular pressure.
 Prior to joining Telor, Rossolillo served as a technical consultant to the pharmaceutical and device industry. During his more than 16 years in the industry, Rossolillo has served as plant manager for Invenex Laboratories Inc., and as operations manager for Solopak Laboratories. He received his B.S. in biology at Metropolitan State College in Denver.
 Potter has more than 16 years' experience in the management of pharmaceuticals manufacturing. Potter previously served for more than five years at Biogen, Inc., most recently as manager, aseptic fill operations. He has also served as a manufacturing supervisor for Codman & Shurtleff, a Johnson & Johnson Company, and as an in-process control manager with Pentcal, Inc. He received his B.A. in biology at the University of Massachusetts, Boston.
 Telor Ophthalmic Pharmaceuticals, Inc. is developing innovative, proprietary products for the treatment of age-related eye diseases. The company's initial products in development are for controlling intraocular pressure following surgery and in glaucoma, and for other diseases of the eye. Telor began operations in 1989 and has its headquarters in Woburn.
 -0- 8/24/92
 /CONTACT: Stephen J. Riggi, Ph.D., president and CEO of Telor, 617-937-0393, or Lynne Brum of Feinstein Partners, 617-577-8110, for Telor/ CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER


CN -- NE001 -- 2875 08/25/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 25, 1992
Words:384
Previous Article:RALLY'S TO ACQUIRE 14 RESTAURANTS IN ARIZONA
Next Article:UNILAB ANNOUNCES THAT ANDREW BAKER ASSUMES FULL TIME ROLE AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Topics:


Related Articles
TELOR OPHTHALMIC PHARMACEUTICALS BEGINS CLINICAL TRIALS WITH PRODUCT TO PREVENT EYE SURGERY COMPLICATION
FREDERICK H. GARBER JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC. AS VICE PRESIDENT OF MARKETING
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP; APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER
TELOR OPHTHALMIC PHARMACEUTICALS, INC. ANNOUNCES THE APPOINTMENT OF SOPHANN IM, PH.D., TO MANAGER OF PHARMACEUTICAL DIVISION
TELOR ACQUIRES EXCLUSIVE RIGHTS TO CELL PROTECTION PROTEINS
TELOR OPHTHALMIC PHARMACEUTICALS, INC. SELLS 375,000 SHARES OF COMMON STOCK THROUGH EXERCISE OF OVER-ALLOTMENT
TELOR APPOINTS MICHAEL H. SILVERMAN, M.D., TO EXECUTIVE DIRECTOR, CLINICAL RESEARCH
TELOR OPHTHALMIC PHARMACEUTICALS, INC. INITIATES PHASE II CLINICAL TRIALS TO EVALUATE TEKRON AS A NEW TREATMENT FOR GLAUCOMA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters